MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

IWG Proposes New Clinical-Biological Definition for Diagnosing Alzheimer’s Disease

NextEdge Admin

07 Nov 2024

2 min 43 sec

JAMA Neurology,The International Working Group (IWG)

The International Working Group (IWG) has proposed a new definition of Alzheimer's disease, emphasizing that cognitive deficits must be present alongside brain amyloid to make a diagnosis. This approach, presented at the Clinical Trials on Alzheimer's Disease (CTAD) meeting and published in *JAMA Neurology*, contrasts with a recent Alzheimer's Association (AA) workgroup’s biological definition, which allows diagnosis based solely on positive biomarkers, even if cognitive symptoms are absent. The IWG definition highlights Alzheimer's as a "clinical-biological entity," requiring both cognitive symptoms and biomarkers for diagnosis.

Howard Feldman, MD, from UC San Diego, explained that the IWG's definition permits an early Alzheimer's diagnosis when mild cognitive signs are observed. The IWG framework addresses concerns that diagnosing cognitively normal individuals with only positive biomarkers, as proposed by the AA, could lead to false positives. The AA's biological definition reflects practices in cancer and heart disease diagnosis, but IWG members argue this may wrongly label asymptomatic individuals as having Alzheimer’s. Bruno Dubois, MD, a lead IWG member, warned that many biomarker-positive individuals might never develop symptomatic Alzheimer's.

The IWG categorizes individuals based on symptoms and biomarker status: those with cognitive impairment and positive biomarkers have Alzheimer's disease, cognitively normal individuals with amyloid biomarkers are "asymptomatic at risk," and those with genetic risk factors or specific biomarkers are "presymptomatic." Ronald Petersen, MD, from the Mayo Clinic, noted that while the AA recommends against testing asymptomatic individuals outside research, the growing availability of biomarker tests raises ethical concerns. The IWG thus maintains that Alzheimer's should remain a diagnosis grounded in both clinical symptoms and pathology, rather than solely biomarker positivity, preserving the focus on risk versus disease.